Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Sallmon, H; Koestenberger, M; Avian, A; Reiterer, F; Schwaberger, B; Meinel, K; Cvirn, G; Kurath-Koller, S; Gamillscheg, A; Hansmann, G.
Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension.
J Perinatol. 2022; 42(6):781-787 Doi: 10.1038/s41372-022-01374-w [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Koestenberger Martin; Sallmon Hannes
Co-authors Med Uni Graz: Avian Alexander; Cvirn Gerhard; Gamillscheg Andreas; Köstenbauer Katharina; Kurath-Koller Stefan; Reiterer Friedrich; Schwaberger Bernhard
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: OBJECTIVE: Extremely low gestational age newborns (ELGANs) represent an especially vulnerable population. Herein, we aimed to determine incidence and severity of pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) in extremely immature ELGANs (gestational age: 23^0/6-25^6/7 weeks). METHODS: In this prospective observational cohort study, we assessed BPD-PH by means of several echocardiography markers and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at 3 and 12 months of chronological age. In addition, we analyzed incidence and efficacy of pharmacologic treatment for BPD-PH. RESULTS: At 3 months 15/34 ELGANs had echocardiographic evidence of BPD-PH, while at 12 months of age 6/34 still had PH. PH-targeted therapy consisted of sildenafil monotherapy in 11 and dual oral combination therapy (sildenafil and macitentan) in four ELGANs at 3 and 12 months. CONCLUSION: 44% (15/34) of ELGANs developed BPD-PH. All received PH-targeted pharmacotherapy at 3 months, leading to hemodynamic improvements at 12 months in most infants.
Find related publications in this database (using NLM MeSH Indexing): Adult - administration & dosage; Biomarkers - administration & dosage; Bronchopulmonary Dysplasia - complications, epidemiology; Child - administration & dosage; Female - administration & dosage; Gestational Age - administration & dosage; Humans - administration & dosage; Hypertension, Pulmonary - drug therapy, epidemiology, etiology; Infant - administration & dosage; Infant, Extremely Premature - administration & dosage; Infant, Newborn - administration & dosage; Pregnancy - administration & dosage; Prospective Studies - administration & dosage; Sildenafil Citrate - therapeutic use; Young Adult - administration & dosage

© Med Uni Graz • Imprint